MX2019013014A - Tratamiento de carcinoma hepatocelular. - Google Patents

Tratamiento de carcinoma hepatocelular.

Info

Publication number
MX2019013014A
MX2019013014A MX2019013014A MX2019013014A MX2019013014A MX 2019013014 A MX2019013014 A MX 2019013014A MX 2019013014 A MX2019013014 A MX 2019013014A MX 2019013014 A MX2019013014 A MX 2019013014A MX 2019013014 A MX2019013014 A MX 2019013014A
Authority
MX
Mexico
Prior art keywords
hepatocellular carcinoma
treatment
lenvatinib
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2019013014A
Other languages
English (en)
Inventor
Toshiyuki Tamai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019013014A publication Critical patent/MX2019013014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta descripción proporciona métodos para tratar un carcinoma hepatocelular (por ejemplo, HCC irresecable) con lenvatinib o una sal farmacéuticamente aceptable del mismo. La descripción también abarca pautas posológicas descritas en este documento de lenvatinib o una sal farmacéuticamente aceptable del mismo para su uso en el tratamiento de carcinoma hepatocelular (por ejemplo, carcinoma hepatocelular irresecable) de acuerdo con cualquiera de los métodos descritos en este documento. También se describen dosificaciones y modificaciones de dosis particularmente útiles tras la manifestación de uno o más acontecimientos adversos.
MX2019013014A 2017-05-16 2018-05-15 Tratamiento de carcinoma hepatocelular. MX2019013014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762506900P 2017-05-16 2017-05-16
PCT/JP2018/018810 WO2018212202A1 (en) 2017-05-16 2018-05-15 Treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
MX2019013014A true MX2019013014A (es) 2020-08-06

Family

ID=64273837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013014A MX2019013014A (es) 2017-05-16 2018-05-15 Tratamiento de carcinoma hepatocelular.

Country Status (12)

Country Link
US (2) US20200197384A1 (es)
EP (1) EP3624800A4 (es)
JP (1) JP2020519576A (es)
KR (1) KR20200013644A (es)
CN (1) CN110831597A (es)
AU (1) AU2018269996A1 (es)
BR (1) BR112019023064A2 (es)
CA (1) CA3061888A1 (es)
MX (1) MX2019013014A (es)
RU (1) RU2019134940A (es)
SG (1) SG11201910100PA (es)
WO (1) WO2018212202A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728000A (zh) * 2019-10-21 2022-07-08 荷兰癌症研究所-安东尼·范·雷文虎克医院基金会 治疗癌症的新型药物组合

Also Published As

Publication number Publication date
SG11201910100PA (en) 2019-11-28
EP3624800A1 (en) 2020-03-25
US20200197384A1 (en) 2020-06-25
JP2020519576A (ja) 2020-07-02
CN110831597A (zh) 2020-02-21
US20220040168A1 (en) 2022-02-10
CA3061888A1 (en) 2018-11-22
EP3624800A4 (en) 2021-02-17
RU2019134940A (ru) 2021-06-16
RU2019134940A3 (es) 2021-08-20
AU2018269996A1 (en) 2019-11-21
WO2018212202A1 (en) 2018-11-22
BR112019023064A2 (pt) 2020-06-09
KR20200013644A (ko) 2020-02-07

Similar Documents

Publication Publication Date Title
PH12017502079A1 (en) Treatment of beta-thalassemia using actrii ligand traps
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2019012884A (es) Terapia de combinacion.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2018004309A (es) Terapias combinadas para tratar el cancer.
MX2014003180A (es) Metodos para tratar vhc.
MX2018009173A (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2018000240A (es) Metodos para tratar el vhc.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2019013014A (es) Tratamiento de carcinoma hepatocelular.
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018012193A (es) Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus.